Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

Expert Review of Anticancer Therapy

Volumn 10, Issue 9, 2010, Pages 1407-1418

  Uckun, Fatih M ^a,b   Qazi, Sanjive ^c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

leukemia; lymphoma; nanotechnology; rational drug design; RNA interference; spleen tyrosine kinase; tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; C 61; CHECKPOINT KINASE 1; DASATINIB; DOXORUBICIN; FOSTAMATINIB DISODIUM; MICROTUBULE ASSOCIATED PROTEIN; PENTAPEPTIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; R 406; R 788; SMALL INTERFERING RNA; STAT3 PROTEIN; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CELL MATURATION; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME ACTIVITY; FATIGUE; GENE EXPRESSION; HUMAN; HYPERTENSION; IONIZING RADIATION; LEUKEMIA; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SPLEEN; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION;

APOPTOSIS; DRUG DESIGN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 77956654136     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.112     Document Type: Review

References (72)

1. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of SYK protein tyrosine kinase. J. Biochem. 130, 177-186 (2001).
2. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378, 303-306 (1995).
3. Moon K, Post CB, Durden L et al. Molecular basis for a direct interaction between the SYK protein tyrosine kinase and phosphoinositide 3-kinase. J. Biol. Chem. 280, 1543-1551 (2005).
4. Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the SYK autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J. Exp. Med. 182, 1815-1823 (1995).
5. Beitz LO, Fruman A, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem. 274, 32662-32666 (1999).
6. Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 13, 817-827 (2000).
7. Buhl AM, Cambier JC. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor mediated activation of Bruton's tyrosine kinase. J. Immunol. 162, 4438-4446 (1999).
8. Ingham RJ, Santos L, Dang-Lawson M et al. The Gabl locking protein links the B cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway andto the SHP2 tyrosine phosphatase. J. Biol. Chem. 276, 12257-12265 (2001).
9. DeFranco AL. Transmembrane signaling by antigen receptors of B and T lymphocytes. Curr. Opin. Cell Biol. 7, 163-175 (1995).
10. Hsueh RC, Scheuermann RH. Tyrosine kinase activation in the decision between growth, differentiation, and death responses initiated from the B cell antigen receptor. Adv. Immunol. 75, 283-316 (2000).
11. Koretzky GA, Abtahian F, Silverman MA. SLP76 and SLP65: complex regulation of signaling in lymphocytes and beyond. Nat. Rev. Immunol. 6, 67-78 (2006).
12. Law CL, Sidorenko SP, Chandran KA et al. Molecular cloning of human Syk. A B cell protein tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex. J. Biol. Chem. 269, 12310-12319 (1994).
13. Leseux, L, Hamdi SM, Al Saati T et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108, 4156-4162 (2006).
14. Ding J, Takano T, Gao S et al. Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress. J. Biol. Chem. 275, 30873-30877 (2000).
15. Qin S, Minami Y, Hibi M, Kurosaki T, Yamamura H. Syk-dependent and-independent signaling cascades in B cells elicited by osmotic and oxidative stress. J. Biol. Chem. 272, 2098-2103 (1997).
16. Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/ lymphoma cells exposed to oxidative stress. Proc. Natl Acad. Sci. USA 107, 2902-2907 (2010).
17. Peters JD, Furlong MT, Asai DJ, Harrison ML, Geahlen RL. Syk, activated by crosslinking the B cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha tubulin on tyrosine. J. Biol. Chem. 271, 4755-4762 (1996).
18. Sulimenka V, Draberova E, Sulimenka T et al. Regulation of microtubule formation in activated mast cells by complexes of y tubulin with Fyn and Syk kinases. J. Immunol. 176, 7243-7253 (2006).
19. Faruki S, Geahlen RL, Asai DJ. Syk-dependent phosphorylation of microtubules in activated B lymphocytes. J. Cell Sci. 113, 2557-2565 (2000).
20. Lebouvier T, Scales TM, Hanger DP et al. The microtubule-associated protein Tau is phosphorylated by Syk. Biochim. Biophys. Acta 1783, 188-192 (2008).
21. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5Å and location of the taxol binding site. Nature 375, 424-427 (1995).
22. Zyss D, Montcourrier P, Vidal B et al The SYK tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 65, 10872-10880 (2005).
23. He J, Takano T, Gao S et al. Syk is required for p38 activation and G2/M arrest in B-cells exposed to oxidative stress. Antioxid. Redox Signal. 4, 509-515 (2002).
24. Wossning T, Herzog S, Kohler F et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J. Exp. Med. 13, 2829-2840 (2006).
25. Baudot AD, Jeandel PY, Mouska X et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCd and proteasome-dependent regulation of Mcl-1 expression. Oncogene 28, 3261-3273 (2009).
26. Buchner M, Fuchs S, Prinz G et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69, 5424-5432 (2009).
27. Chen L, Monti S, Juszczynski P et al SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large cell lymphoma. Blood 111, 2230-2237 (2008).
28. Gobessi S, Laurenti L, Longo PG et al Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B-cells. Leukemia 23, 686-697 (2009).
29. Quiroga MP, Balakrishnan K, Kurtova AV et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specifc targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114, 1029-1037 (2009).
30. Rinaldi A, Kwee I, Taborelli M et al Genomic and expression profling identifes the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Hematol. 132, 303-316 (2006).
31. Young RM, Hardy IR, Clarke RL et al Mouse models of non-Hodgkin's lymphoma reveal Syk as an important therapeutic target. Blood 113, 2508-2516 (2009).
32. Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Hematol. 149, 508-517 (2010).
33. Yu K, Ganesan K, Tan LK et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet. 4, e1000129 (2008).
34. Weston VJ, Austen B, Wei W et al Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF KB survival pathway signaling. Blood 104, 1465-1473 (2004).
35. Marston E, Weston V, Jesson J et al. Stratifcation of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood 113, 117-126 (2009).
36. Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 5, 727-728 (2009).
37. Uckun FM, Dibirdik I, Qazi S. Augmentation of the anti-leukemic potency of total body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK). Radiat. Res. (2010) (In press).
38. Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C. Polo-like kinase 1 (PLK1) as a molecular target to overcome Syk-mediated resistance of B-lineage acute lymphoblastic leukemia cells to oxidative stress. Br. J. Hematol. 148, 714-725 (2010).
39. Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin. Ther. Patents 19 (10), 1361-1376 (2009).
40. Hirabayashi A, Mukaiyama H, Kobayashi H et al. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazole[4,3-c] pyrimidine and 1,2,4-triazolo[1,5-c] pyrimidine derivatives. Biorg Med. Chem. 16, 7347-7357 (2008).
41. Friedberg JW, Sharman J, Sweetham J et al Inhibition of SYK with fostamatinib disodium has signifcant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578-2585 (2010).
42. Atwell S, Adams JM, Badger J et al A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827-55832 (2004).
43. Villasenor AG, Kondru R, Ho H et al Structural insights for design of potent spleen tyrosine kinase inhibitors from crystollagraphic analysis of three inhibitor complexes. Chem. Biol. Drug Des. 73, 466-470 (2009).
44. Marsilje TH, Milkiewicz KL, Hangauer DG. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives. Bioorg. Med. Chem. Lett. 10, 477-481 (2000).
45. Ye G, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr. Opin. Investig Drugs 9, 605-613 (2008).
46. Matsuda M, Park JG, Wang DC et al Abrogation of the Fc y receptor IIA-mediated phagocytic signal by stem-loop Syk antisense oligonucleotides. Mol. Biol Cell 7, 1095-1106 (1996).
47. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008).
48. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14, 1310-1316 (2008).
49. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5, 1909-1917 (2006).
50. Cheng WWK, Das D, Suresh M, Allen TM. Expression and purifcation of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim. Biophys. Acta 1768, 21-29 (2007).
51. Cheng WWK, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J. Control. Release 126, 50-58 (2008).
52. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149 (2004).
53. Zhukovsky E, Horton H, Lawrence CE et al. XmAb5574: in vitro and in vivo effcacy of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia and its effect on B cells in non-human primates. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 3078).
54. Kugler M, Stein C, Schwenkert M et al. Stabilization and humanization of a single-chain Fv antibody fragment specifc for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng. Des. Sel. 22, 135-147 (2009).
55. Zhang J, Tang Y, Shen H, Qian B. Targeting and internalization of sterically stabilized liposome modifed with ZCH-4-2E8. J. Huazhong Univ. Sci. Technol. 29, 273-280 (2009).
56. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin. Hematol. 46, 52-63 (2009).
57. Trigg ME, Sather H, Reaman GH et al. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk. Lymphoma 49, 1142-1154 (2008).
58. Seibel NL, Steinherz PG, Sather HN et al. Early postinduction intensifcation therapy improves survival for children and adolescents with high risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 111, 2548-2555 (2008).
59. Gaynon PS. Childhood acute lymphoblastic leukemia and relapse. Br. J. Haematol. 131, 579-587 (2005).
60. Gaynon PS, Harris RE, Altman AJ et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group Study CCG-1941. J. Clin. Oncol. 24, 3150-3156 (2006).
61. Eapen M, Raetz E, Zhang MJ et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107, 4961-4967 (2006).
62. Malempati S, Gaynon PS, Sather H, La MK, Stork LC. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J. Clin. Oncol. 25, 5800-5807 (2007).
63. Roy A, Cargill A, Love S et al. Outcome after frst relapse in childhood acute lymphoblastic leukemia-lessons from the United Kingdom R2 trial. Br. J. Hematol. 130, 67-75 (2005).
64. Bailey LC, Lange BJ, Rheinhold SR, Bunin NJ. Bone marrow relapse in paediatric acute lymphoblastic leukemia. Lancet Oncol. 9, 873-883 (2008).
65. Roy A, Cargill A, Love S et al. Outcome after frst relapse in childhood acute lymphoblastic leukemia-lessons from the United Kingdom R2 trial. Br. J. Hematol. 130, 67-75 (2005).
66. Uckun FM, Morar S, Qazi S. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias. Br. J. Haematol. 135, 500-508 (2006).
67. Uckun FM, Chandan-Langlie M, Jaszcz W, Obuz V, Waddick K, Song C W. Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. Cancer Res. 53, 1431-1436 (1993).
68. Uckun FM, Jaszcz W, Chandan-Langlie M, Waddick KG, Gajl-Peczalska K, Song C W. Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest. 91, 1044-1051 (1993).
69. Hahn CK, Berchuk JE, Ross KN et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16, 281-294 (2009).
70. Song Z, Lu P, Furman RR et al. Activities of SYK and PLCg2 predict apoptotic response of CLL cells to Src tyrosine kinase inhibitor dasatinib. Clin. Cancer Res. 16, 587-599 (2010).
71. Dennehy KM, Ferwerda G, Faro-Trindade I et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur. J. Immunol. 38, 500-506 (2008).
72. Gevrey JC, Isaac BM, Cox D. SYK is required for monocyte/ macrophage chemotaxis to CX3CL1 (Fracalkine). J. Immunol. 175, 3737-3745 (2005).